| scholarly article | Q13442814 |
| P50 | author | Dana Gabuzda | Q91131980 |
| Dominic E. Dwyer | Q100529715 | ||
| Steven L Wesselingh | Q106249863 | ||
| Anthony L. Cunningham | Q39034658 | ||
| Victoria A. Lawson | Q48088830 | ||
| P2093 | author name string | Wayne Dyer | |
| Kim Wilson | |||
| Paul R Gorry | |||
| John Sullivan | |||
| Erin E Verity | |||
| Melissa Churchill | |||
| Dale A McPhee | |||
| Dimitra Zotos | |||
| Catherine Chatfield | |||
| Jennifer Learmont | |||
| P2860 | cites work | Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1 | Q24516944 |
| Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group | Q24524085 | ||
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients | Q28284190 | ||
| Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection | Q29614956 | ||
| Importance of the nef gene for maintenance of high virus loads and for development of AIDS | Q29618369 | ||
| Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation | Q33346236 | ||
| Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort | Q33443744 | ||
| Identification of a new recipient in the Sydney Blood Bank Cohort: a long-term HIV type 1-infected seroindeterminate individual | Q33443926 | ||
| An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). | Q33444710 | ||
| Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques | Q33490720 | ||
| Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity | Q33847458 | ||
| Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection | Q33847697 | ||
| Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV | Q74486164 | ||
| Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection | Q77386243 | ||
| Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations | Q81091989 | ||
| Identification of attenuated variants of HIV-1 circulating recombinant form 01_AE that are associated with slow disease progression due to gross genetic alterations in the nef/long terminal repeat sequences | Q81824936 | ||
| Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines | Q33911935 | ||
| Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source | Q34301899 | ||
| Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele | Q34545588 | ||
| Live attenuated HIV vaccines: pitfalls and prospects | Q35748470 | ||
| Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. | Q35853750 | ||
| High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. | Q35872157 | ||
| Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. | Q35895851 | ||
| Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes | Q36354762 | ||
| An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1 | Q36687524 | ||
| Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus | Q38362352 | ||
| Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome | Q39031676 | ||
| Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group | Q39490780 | ||
| Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor | Q39578202 | ||
| Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody | Q40318256 | ||
| Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. | Q40914854 | ||
| Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion | Q42543411 | ||
| Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection | Q42604793 | ||
| Activation of human immunodeficiency virus type 1 by DNA damage in human cells | Q43571106 | ||
| Isolation of HIV from Australian patients with AIDS, AIDS related conditions and healthy antibody positive individuals | Q44159732 | ||
| Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study | Q44976761 | ||
| Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies | Q45168377 | ||
| Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. | Q45420564 | ||
| Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain | Q45734125 | ||
| Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy | Q45734364 | ||
| Characterization of immune escape viruses from a macaque immunized with live-virus vaccine and challenged with pathogenic SHIVKU-1. | Q45739989 | ||
| Partial "repair" of defective NEF genes in a long-term nonprogressor with human immunodeficiency virus type 1 infection | Q45745479 | ||
| Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors | Q45750292 | ||
| Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors | Q45759636 | ||
| Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection | Q45760115 | ||
| Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine | Q45763014 | ||
| Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. | Q45780550 | ||
| Rapid full-length genomic sequencing of two cytopathically heterogeneous Australian primary HIV-1 isolates | Q47871488 | ||
| Setting the record straight: IAPAC's HIV vaccine initiative. International Association of Physicians in AIDS Care. | Q53325558 | ||
| Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. | Q53977964 | ||
| Long-term symptomless HIV-1 infection in recipients of blood products from a single donor | Q57076560 | ||
| Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection | Q59309189 | ||
| Longitudinal Analysis ofnef/Long Terminal Repeat–Deleted HIV‐1 in Blood and Cerebrospinal Fluid of a Long‐Term Survivor Who Developed HIV‐Associated Dementia | Q62572416 | ||
| Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa | Q73280230 | ||
| Novel campaign to test live HIV vaccine | Q73680570 | ||
| Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment | Q73960707 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 9268-9278 | |
| P577 | publication date | 2007-06-13 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions | |
| P478 | volume | 81 |
| Q43215260 | Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers |
| Q44780665 | Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain |
| Q36926697 | HIV-1 Nef: at the crossroads |
| Q41868926 | Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses |
| Q34115280 | High Viral Fitness during Acute HIV-1 Infection |
| Q33827771 | IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines |
| Q36421895 | Lipid metabolism in patients infected with Nef-deficient HIV-1 strain |
| Q36988552 | Macrophage Tropism and Cytopathicity of HIV-1 Variants Isolated Sequentially from a Long-Term Survivor Infected with nef-Deleted Virus |
| Q37078512 | Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection |
| Q34109778 | Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. |
| Q34007084 | Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo |
| Q92702651 | Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Δ32 heterozygous and HLA-B57 genotype |
| Q36638489 | Short communication: neutralizing antibodies in HIV-1-infected Brazilian individuals |
Search more.